Kukje Pharma Co Ltd (002720) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Kukje Pharma Co Ltd stock KRW 2,557, price KRW 3,200, that is 20.1% below the price, quality 51 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 3,045 KRW – 7,893 KRW · fair‑value band 1,225 KRW – 4,142 KRW · the 3,200 KRW price screens above the 2,557 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Kukje Pharma Co in your weekly email
Every Wednesday you see whether Kukje Pharma Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products.
Show moreShow less
Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, other ETC products, and other products.
Kukje Pharma Co., Ltd. was founded in 1959 and is headquartered in Seongnam-si, South Korea.
Stock analysis
Kukje Pharma Co Ltd (002720) currently trades at 3,200 KRW, while our model-based Fair Value estimate is 2,557 KRW, 20% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 5,016 KRW per share, and 10 of the 25 models we run sit above the 3,200 KRW price.
Bear case: the Dividend Discount group reads lowest at 341.86 KRW, and 15 of the 25 models stay below the price. Data coverage for this calculation is high.
Scenario range: 1,225 KRW (bear) to 4,142 KRW (bull), the price of 3,200 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kukje Pharma Co Ltd reported revenue of 175B KRW in FY2025 versus 120B KRW in FY2021, a compound +10.0%/yr. Reported net income was 5.7B KRW in FY2025.
Key figures
Market cap 67.7B KRW (≈ $50.1M) Micro · P/E ratio 13.7 · P/S ratio 0.37 · EPS (TTM) 236.35 KRW · Dividend yield 0.9% · Net margin 2.8% · Return on equity 5.2% · Return on assets (EBIT) 1.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −20%, 002720 screens cheaper than that median.
Fair Value models
Bear1,225 KRWFair Value 2,557 KRWBull4,142 KRW
Price 3,200 KRW · Downside -20.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (176.95 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.5%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.18.5% vs 19.7%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 4%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+35.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +32.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−20.1% · Below median
Profitability
Return on equity (12 months)5.2% · Below median
Return on assets3.1% · Below median
Net margin (12 months)2.8% · Below median
Operating margin (12 months)4.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)7.3% · Above median
Dividend yield (12 months)0.9% · Below median
Balance sheet
Debt / equity0.28× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)13.7× · Cheaper than median
P/B0.69× · Cheapest 25%
P/S (12 months)0.37× · Cheapest 25%
Price / free cash flow (fiscal year)34.4× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kukje Pharma Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002720
Frequently asked questions
Is Kukje Pharma Co Ltd (002720) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2,557 KRW versus a price of 3,200 KRW, about 20% lower (overvalued).
What is the fair value of 002720?
Our model-based fair value for Kukje Pharma Co Ltd is 2,557 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,200 KRW.
What is the quality score of 002720?
Kukje Pharma Co Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kukje Pharma Co Ltd (002720)?
Our model-based price target is the fair value of 2,557 KRW (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 1,225 KRW, optimistic scenario 4,142 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Kukje Pharma Co Ltd stock forecast for 2026?
Our models put fair value at 2,557 KRW, about 20% lower versus a price of 3,200 KRW (overvalued). Cautious scenario 1,225 KRW, optimistic scenario 4,142 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kukje Pharma Co Ltd (002720)?
Kukje Pharma Co Ltd reported trailing-twelve-month revenue of about 181B KRW (latest available figure, as of Nov 9, 2026).
Does Kukje Pharma Co Ltd pay a dividend?
Kukje Pharma Co Ltd currently shows a dividend yield of 0.94% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Kukje Pharma Co Ltd (002720) and when is the ex-dividend date?
Kukje Pharma Co Ltd pays a dividend of 30.00 KRW per share a year, a dividend yield of 0.9%. The last ex-dividend date was Mar 12, 2026. The payout ratio is 12.7% of earnings. Free cash flow covers the dividend 3.10 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Kukje Pharma Co Ltd (002720)?
For today's price to be fair in a discounted-cash-flow model, Kukje Pharma Co Ltd would have to grow free cash flow by +35.1 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 002720 use?
Our models discount Kukje Pharma Co Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Kukje Pharma Co Ltd that is +35.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Kukje Pharma Co Ltd (002720) delivered so far?
Over the past 5 years revenue at Kukje Pharma Co Ltd grew +6.1 % a year. The price currently implies free-cash-flow growth of +35.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Kukje Pharma Co Ltd (002720) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Kukje Pharma Co Ltd (+35.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Kukje Pharma Co Ltd (002720)?
The free-cash-flow yield on the price is 3.02 %: that much free cash flow Kukje Pharma Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Kukje Pharma Co Ltd (002720)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kukje Pharma Co Ltd it is 2,557 KRW per share (as of Nov 9, 2026), against a price of 3,200 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Kukje Pharma Co Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 002720 trades above its calculated fair value: price 3,200 KRW, fair value 2,557 KRW, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002720?
No. The price is what the market pays today (3,200 KRW); the fair value is what the company's own numbers justify (2,557 KRW). For Kukje Pharma Co Ltd the two are 642.92 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kukje Pharma Co Ltd worth?
The market values Kukje Pharma Co Ltd at about 67.7B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,200 KRW; our models calculate a fair value of 2,557 KRW per share.
What do the bullish and bearish scenarios say about 002720?
Our models span a range for Kukje Pharma Co Ltd: cautious scenario 1,225 KRW, base 2,557 KRW, optimistic 4,142 KRW per share (as of Nov 9, 2026, price 3,200 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002720?
Kukje Pharma Co Ltd trades at a price-to-earnings ratio of 13.7 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 2,557 KRW is built from several models across several years. Other multiples: P/B 0.7, P/S 0.4, EV/EBITDA 10.7.
How solid is the balance sheet of Kukje Pharma Co Ltd (002720)?
Balance-sheet figures for Kukje Pharma Co Ltd (as of Nov 9, 2026): return on equity 5.2%, debt of 0.28 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 002720 from its 52-week high?
Kukje Pharma Co Ltd trades at 3,200 KRW, about 39% below its 52-week high of 5,230 KRW and 5% above the low of 3,045 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 2,557 KRW is for.
Which stocks are comparable to Kukje Pharma Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kukje Pharma Co Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 3,200 KRW, calculated fair value 2,557 KRW (−20%), Quality Score 51/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002720 calculated?
We run Kukje Pharma Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 2,557 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Kukje Pharma Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kukje Pharma Co Ltd (002720)?
The closing price on Nov 6, 2026 was 3,200 KRW. Our model-based fair value is 2,557 KRW, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kukje Pharma Co Ltd right now?
The model range is unusually wide (1,225 KRW to 4,142 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Kukje Pharma Co Ltd
How large is the market capitalisation of Kukje Pharma Co Ltd (002720)?
The market capitalisation of Kukje Pharma Co Ltd is 67.7B KRW (≈ $50.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kukje Pharma Co Ltd (002720)?
The price-to-sales ratio of Kukje Pharma Co Ltd is 0.37 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kukje Pharma Co Ltd (002720)?
Earnings per share at Kukje Pharma Co Ltd are 236.35 KRW (price ÷ EPS = P/E 13.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kukje Pharma Co Ltd (002720)?
The dividend yield of Kukje Pharma Co Ltd is 0.9% (payout 12.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kukje Pharma Co Ltd (002720)?
The net margin of Kukje Pharma Co Ltd is 2.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kukje Pharma Co Ltd (002720)?
The return on equity (ROE) of Kukje Pharma Co Ltd is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kukje Pharma Co Ltd (002720)?
On an EBIT basis the return on assets of Kukje Pharma Co Ltd is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kukje Pharma Co Ltd (002720)?
The operating margin of Kukje Pharma Co Ltd is 4.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kukje Pharma Co Ltd (002720)?
Revenue at Kukje Pharma Co Ltd is growing +7.3% versus a year earlier (3y avg +11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kukje Pharma Co Ltd (002720)?
Earnings per share at Kukje Pharma Co Ltd are growing −39.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Kukje Pharma Co Ltd (002720) carry?
The net debt of Kukje Pharma Co Ltd is 19.3B KRW (fiscal year 2025, ≈ 9.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kukje Pharma Co Ltd in the live analysis
One click puts Kukje Pharma Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026